Research Article

Oncology Research Institute (IPON), Federal University of Triângulo Mineiro (UFTM), Uberaba, MG, Brazil

Department of Gynecology and Obstetrics, Federal University of Triangulo Mineiro (UFTM), Uberaba, MG, 38.025-350, Brazil

Search for more papers by this author

Márcia A Michelin

*Author for correspondence:

E-mail Address: marcia.michelin@uftm.edu.br

https://orcid.org/0000-0003-0842-8805

Oncology Research Institute (IPON), Federal University of Triângulo Mineiro (UFTM), Uberaba, MG, Brazil

Immunology Discipline, Federal University of Triângulo Mineiro (UFTM), Uberaba, MG, 38.025-500, Brazil

Search for more papers by this author

Published Online:21 Dec 2023https://doi.org/10.2217/imt-2021-0097

View article

Abstract

Objective: To evaluate the behavior of adhesion molecules ICAM-1 and ICAM-2 in dendritic cell (DC) immunotherapy. Materials & methods: 88 female Balb/c mice were divided into experimental groups. Tumors and lymph nodes were evaluated 7 and 14 days after immunotherapy. Results: Higher mean fluorescence intensity of ICAM-1 in the lymph nodes and tumors in the tumor group at 14 days was observed. Higher mean fluorescence intensity of ICAM-2 in the tumor DC vaccine group was observed after 14 days. A positive correlation was observed in the lymph nodes with ICAM-1 against tumoral volume in the tumor group. A negative correlation was found between ICAM-2 and tumoral volume in the lymph nodes of the tumor group. Conclusion: An increase in ICAM-2 in tumor DC vaccine and a decrease in ICAM-1 suggests the DC vaccine positively influences the immune system and that ICAM-2 could be a marker of good prognosis.

Plain language summary

Dendritic cell vaccines are a type of immunotherapy that can reduce tumor volume and increase the expression of immune proteins that fight cancer. However, some improvements are needed to better analyze tumor development and cell characteristics in patients given these vaccines. This research was designed to clearly describe what happens to the body's natural defense during treatment with dendritic cell vaccines. Animals were induced to develop breast cancer and parts of their immune system were analyzed after receiving a dendritic cell vaccine. A specific molecule, called ICAM-2, which is involved in the immune response, was linked to a reduction in tumor volume. The authors conclude that ICAM-2 might be a marker of good prognosis in patients receiving a dendritic cell vaccine.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Asna N, Livoff A, Batash R et al. Radiation therapy and immunotherapy–a potential combination in cancer treatment. Curr. Oncol. 25(5), e454–e460 (2018).
Medline CASGoogle Scholar
2. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int. J. Med. Sci. 9(3), 193–199 (2012).
MedlineGoogle Scholar
3. Baskar R, Dai J, Wenlong N, Yeo R, Yeoh KW. Biological response of cancer cells to radiation treatment. Front Mol. Biosci. 1, 1–9 (2014).
Medline CASGoogle Scholar
4. Lee JY, Lee HT, Shin W et al. Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat. Commun. 7, 1–10 (2016).
Google Scholar
5. Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med. J. 6, 1–9 (2015).
Google Scholar
6. Calmeiro J, Carrascal MA, Tavares AR et al. Dendritic cell vaccines for cancer immunotherapy: the role of human conventional type 1 dendritic cells. Pharmaceutics 12(2), 1–20 (2020).
Google Scholar
7. Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity 52(1), 17–35 (2020).
Medline CASGoogle Scholar
8. Koury J, Lucero M, Cato C et al. Immunotherapies: exploiting the immune system for cancer treatment. J. Immunol. Res. 2018, 1–16 (2018).
Google Scholar
9. Harjunpää H, Asens ML, Guenther C, Fagerholm SC. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front. Immunol. 10(1078), 1–24 (2019).
MedlineGoogle Scholar
10. Kappelmayer J, Nagy B. The interaction of selectins and PSGL-1 as a key component in thrombus formation and cancer progression. Biomed. Res. Int. 2017, 1–18 (2017).
Google Scholar
11. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 339(1), 269–280 (2010).
Medline CASGoogle Scholar
12. Roland CL, Harken AH, Sarr MG, Barnett CC. ICAM-1 expression determines malignant potential of cancer. Surgery 141(6), 705–707 (2007).
MedlineGoogle Scholar
13. Wang S, Coleman EJ, Pop LM, Brooks KJ, Vitetta ES, Niederkorn JY. Effect of an anti-cd54 (ICAM-1) monoclonal antibody (UV3) on the growth of human uveal melanoma cells transplanted heterotopically and orthotopically in SCID mice. Int. J. Cancer 118(4), 932–941 (2006). • Classic study demonstrating that inhibition of ICAM-1 reduces metastasis formation and tumor development in experimental models of melanoma.
Medline CASGoogle Scholar
14. Figenschau SL, Knutsen E, Urbarova I et al. ICAM1 expression is induced by proinflammatory cytokines and associated with TLS formation in aggressive breast cancer subtypes. Sci. Rep. 8(1), 1–12 (2018).
Medline CASGoogle Scholar
15. Reina M, Espel E. Role of LFA-1 and ICAM-1 in cancer. Cancers (Basel) 9(11), 1–14 (2017).
Google Scholar
16. Cohen S, Haimovich J, Hollander N. Anti-idiotype × anti-LFA-1 bispecific antibodies inhibit metastasis of B cell lymphoma. J. Immunol. 170(5), 2695–2701 (2003).
Medline CASGoogle Scholar
17. Soto MS, O'Brien ER, Andreou K et al. Disruption of tumour-host communication by downregulation of LFA-1 reduces COX-2 and e-NOS expression and inhibits brain metastasis growth. Oncotarget 7(32), 52375–52391 (2016).
MedlineGoogle Scholar
18. Breckpot K, Escors D. Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocr. Metab. Immune Disord. Drug Targets 9(4), 328–343 (2012).
Google Scholar
19. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137(5), 1142–1162 (1973). • Classic paper describing dendritic cells.
Medline CASGoogle Scholar
20. Hsu FS, Su CH, Huang KH. A comprehensive review of US FDA-approved immune checkpoint inhibitors in urothelial carcinoma. J. Immunol. Res. 2017, 1–9 (2017).
Google Scholar
21. Liu Y-J, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat. Immunol. 2(7), 585–589 (2001).
Medline CASGoogle Scholar
22. Clark GJ, Angel N, Kato M et al. The role of dendritic cells in the innate immune system. Microbes Infect. 2(3), 257–272 (2000).
Medline CASGoogle Scholar
23. Fernández-Delgado I, Calzada-Fraile D, Sánchez-Madrid F. Immune regulation by dendritic cell extracellular vesicles in cancer immunotherapy and vaccines. Cancers (Basel) 12(12), 1–23 (2020).
Google Scholar
24. Gallois A, Bhardwaj N. Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment. Front. Immunol. 4(12), 1–8 (2013).
Medline CASGoogle Scholar
25. Kumar C, Kohli S, Bapsy PP et al. Immune modulation by dendritic-cell-based cancer vaccines. J. Biosci. 42(1), 161–173 (2017).
Medline CASGoogle Scholar
26. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12(8), 557–569 (2012). • Cross-presentation is the main feature making dendritic cells professional antigen presenters.
Medline CASGoogle Scholar
27. Chae YK, Choi WM, Bae WH et al. Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer. Sci. Rep. 8(1), 1–10 (2018).
MedlineGoogle Scholar
28. Comrie WA, Li S, Boyle S, Burkhardt JK. The dendritic cell cytoskeleton promotes T cell adhesion and activation by constraining ICAM-1 mobility. J. Cell Biol. 208(4), 457–473 (2015).
Medline CASGoogle Scholar
29. Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 27(1), 74–95 (2017).
Medline CASGoogle Scholar
30. Lozano M, Cid J, Benitez-Ribas D, Otero MJ. Technical challenges in the manufacture of dendritic cell cancer therapies. Eur. Oncol. Haematol. 15(1), 22–28 (2019). • Shows the specificity of the immune response formed through dendritic cells.
Google Scholar
31. Michelin MA, Murta EFC, da Silva SFM. Dynamic analysis of the immunological response of Balb/c mice with experimental breast cancer submitted to immunotherapy treatment of dendritic cell. Braz. J. Dev. 7(7), 66648–66666 (2021).
Google Scholar
32. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942–949 (2004).
Medline CASGoogle Scholar
33. Donizy P, Kaczorowski M, Halon A, Leskiewicz M, Kozyra C, Matkowski R. Paucity of tumor-infiltrating lymphocytes is an unfavorable prognosticator and predicts lymph node metastases in cutaneous melanoma patients. Anticancer Res. 35(1), 351–358 (2015).
MedlineGoogle Scholar
34. Lee KM, Han W, Bin KJ et al. The CD49d⁺/high subpopulation from isolated human breast sarcoma spheres possesses tumor-initiating ability. Int. J. Oncol. 40(3), 665–672 (2012).
Medline CASGoogle Scholar
35. Guo P, Huang J, Wang L et al. ICAM-1 as a molecular target for triple negative breast cancer. Proc. Natl Acad. Sci. USA 111(41), 14710–14715 (2014).
Medline CASGoogle Scholar
36. Knochelmann HM, Dwyer CJ, Bailey SR et al. When worlds collide: th17 and Treg cells in cancer and autoimmunity. Cell Mol. Immunol. 15(5), 458–469 (2018).
Medline CASGoogle Scholar
37. Lee MH, Chang JTC, Liao CT, Chen YS, Kuo ML, Shen CR. Interleukin 17 and peripheral IL-17-expressing T cells are negatively correlated with the overall survival of head and neck cancer patients. Oncotarget 9(11), 9825–9837 (2018).
MedlineGoogle Scholar
38. Khamar B. Active immunotherapy in cancer–current status. Nov. Approaches Cancer Study 1(3), 1–11 (2018).
Google Scholar
39. Schröder C, Witzel I, Müller V et al. Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J. Cancer Res. Clin. Oncol. 137(8), 1193–1201 (2011).
MedlineGoogle Scholar
40. Couffinhal T, Duplaa C, Labat L et al. Tumor necrosis factor-α stimulates ICAM-1 expression in human vascular smooth muscle cells. Arterioscler. Thromb. 13(3), 407–414 (1993). • Shows the relationship between ICAM-1 and TNF-α, a relationship that may be linked to the Th17 profile that has shown great clinical importance in tumor development.
Medline CASGoogle Scholar
41. Lin YC, Lin YC, Wu CC et al. The immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylation. Oncotarget 8(5), 7559–7571 (2017).
MedlineGoogle Scholar
42. Alves JJP, de Fernandes TAAM, De Araújo JMG et al. Th17 response in patients with cervical cancer. Oncol. Lett. 16(5), 6215–6227 (2018).
Medline CASGoogle Scholar
43. Carvalho DFG, Zanetti BR, Miranda L et al. High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer. Oncol. Lett. 13(3), 1925–1931 (2017).
Medline CASGoogle Scholar
44. Dahal LN. The dichotomy of T helper 17 cells in cancer. Nat. Rev. Immunol. 17(9), 233–240 (2017).
MedlineGoogle Scholar
45. Lazarevic V, Chen X, Shim J-H et al. T-bet represses T(H)17 differentiation by preventing Runx1-mediated activation of the gene encoding RORγt. Nat. Immunol. 12(1), 96–104 (2011).
Medline CASGoogle Scholar
46. Feduska JM, Aller SG, Garcia PL et al. ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actinin. Oncogene 34(12), 1553–1562 (2015). •• Reinforces the current thesis by demonstrating that ICAM-2 is more present in tumors with lower metastatic potential.
Medline CASGoogle Scholar
47. Velazquez-Soto H, Real-San Miguel F, Pérez-Tapia SM, Jiménez-Martínez MC. Kinetic changes in B7 costimulatory molecules and IRF4 expression in human dendritic cells during LPS exposure. Biomolecules 12(7), 1–11 (2022).
Google Scholar
48. Fm S, Silva D, Cunha A, Murta EFC, Michelin MA. Different roles of helper T lymphocytes during dendritic cells vaccine in experimental breast cancer. IJEB 60(6), 375–385 (2022). •• Experiment carried out by the current authors' group that demonstrates an increase in costimulatory molecules such as CD86 and MHCII in mice with breast cancer treated with dendritic cell immunotherapy.
Google Scholar
49. Hiraoka N, Yamazakiitoh R, Ino Y et al. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology 140(1), 310–321 (2011).
Medline CASGoogle Scholar
50. Mori H, Kubo M, Kai M et al. T-bet⁺ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer. Breast Cancer Res. Treat. 176(3), 569–577 (2019). • Demonstrates the importance of ICAM-2 and its action in recent stages of tumor development.
Medline CASGoogle Scholar
51. Sasaki Y, Tamura M, Takeda K et al. Identification and characterization of the intercellular adhesion molecule-2 gene as a novel p53 target. Oncotarget 7(38), 61426–61437 (2016). •• Demonstrates that ICAM-2 is correlated with the expression of p53, a protein related to genome surveillance.
MedlineGoogle Scholar

Vol. 16, No. 3

Supplemental Materials

Metrics

Downloaded 38 times

History

Received 22 April 2021

Accepted 23 November 2023

Published online 21 December 2023

Published in print February 2024

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/imt-2021-0097

Author contributions

SFM da Silva designed, performed and wrote the majority of experiments; EFC Murta and MA Michelin planned the experiments and contributed to the analysis/interpretation of the data.

Financial disclosure

This research was supported by the National Council for Scientific and Technological Development (CNPq, grant no. 30211/2015-3), Education Foundation and Uberaba Research (FUNEPU, grant no. 255/2012), Higher Education Personnel Improvement Coordination (CAPES) and Research Support Foundation Minas Gerais state (FAPEMIG, grant no. APQ-02140-21). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download

ICAM2 is related to good prognosis in dendritic cell immunotherapy for cancer

Abstract

Plain language summary

References